Benitec Biopharma Ltd., of Sydney, Australia, selected the Duke Clinical Research Unit in Durham, N.C., as a site for its upcoming Phase I/II first-in-human trial of TT-034 in hepatitis C virus (HCV...NeuroVive Pharmaceutical AB, of Lund, Sweden, said the 600th patient was recruited in its pivotal Phase III European, multicenter CIRCUS (does Cyclosporine ImpRove Clinical oUtcome in ST elevation myocardial infarction patients) trial assessing CicloMulsion in heart reperfusion injury following

It is the first immune cell clinical trial of its kind in China...A follow-on Phase II trial will include clinical markers of muscle health, levels of utrophin expression and other biomarkers...CALM is investigating the clinical efficacy and safety of Cavatak in Stage IIIc or IV melanoma

New data from the analysis showed highly significant improvements in all secondary efficacy measures, including the Clinical Global Impression Severity scale (p < 0.001), the Clinical Global Impression Improvement scale (p = 0.001) and a CGI-I responder analyses (p = 0.002...BrainStorm Cell Therapeutics Inc., of New York, reported some of the final results from a clinical study evaluating its NurOwn technology in 12 amyotrophic lateral sclerosis (ALS) patients...The Phase I/II trial showed a

The company also is preparing a clinical program for marketing in Europe and the U.S

The NX03-0040 prostate cancer clinical study of 150 men is testing low (2.5 mg) and high (15 mg) single doses of NX-1207 for the effect to eradicate or shrink low-grade localized prostate cancer tumors

Secondary objectives of the trial include clinical activity by serum TTR levels...The study showed that Uceris 9 mg gave a statistically significant benefit over placebo for the primary endpoint of clinical and endoscopic remission at week eight...For the Uceris 9-mg group, 17.4 percent of patients achieved clinical and endoscopic remission, compared to 4.5 percent of the placebo group (p = 0.0047

The company also said it is initiating a new financing round – about $6 million in new convertible debt – to fund further clinical development

Proceeds will be used to fund clinical trials of IMO-8400, an agonist of Toll-like receptors 7, 8 and 9, which is in development for autoimmune and inflammatory diseases, as well as for working capital and other general corporate purposes

The study design calls for the collection of 5,250 clinical endpoints, and Merck remains blinded to the actual results of the analysis and to other safety and efficacy data

Janssen and partner Bayer AG, of Leverkusen, Germany, will enroll patients into five global clinical trials, which will involve a total of 28,850 patients

Zealand Pharma A/S, of Copenhagen, Denmark, disclosed in a pipeline update that it plans to advance danegaptide into a single site clinical efficacy study to further profile the peptide drug in cardio protection

The ATX-101 global clinical development program has enrolled more than 2,500 total patients, of which more than 1,500 have been treated with ATX-101, the company said

Vertex Pharmaceuticals Inc., of Cambridge, Mass., said VX-787 in a Phase II influenza challenge study resulted in statistically significant improvements in viral and clinical measurements of infection...Also, 93 percent of people in that dose group showed no clinical symptoms of influenza after three days of treatment, compared to 41 percent of people in the placebo group

Boehringer Ingelheim Pharmaceuticals Inc., of Ridgefield, Conn., part of Boehringer Ingelheim GmbH, reported the first interim results in HCV/HIV co-infected patients from the company's ongoing hepatitis C (HCV) clinical trial program, HCVerso...Polyphor Ltd., of Allschwil, Switzerland, completed a Phase I trial demonstrating the clinical safety and tolerability of its Pseudomonas-specific antibiotic POL7080...The study compared the efficacy and safety of once-weekly Milprosa to daily 8 percent

In total, Ablynx has five products in clinical development and six in preclinical development, of which five are with partners...At the completion of the capital raising, Bionomics will have approximately $26 million in cash.

Dezima Pharma BV, of Naarden, the Netherlands, said it raised €14.2 million (US$18.6 million) for the clinical development of its cholesteryl ester transfer protein (CETP) inhibitor, DEZ-001 (previously TA-8995), and to develop additional earlier-stage dyslipidemia assets...It also will support preparatory work to advance the firm's clinical-stage oncology program, DPX-Survivac, into Phase II development...It will use the proceeds to advance its opthalmic programs through clinical proof of concept

The volasertib clinical development program is the company's most advanced in cell cycle inhibition

In conjunction with the changes in its clinical program, the company said it reduced its work force by 50 percent and outsourced noncritical research and development functions

The company is planning to begin clinical studies in the first half of 2014...The product, a therapeutic antibody, has shown potential in preclinical studies to to reduce damage, allowing pumping efficiency to return to normal levels.